Are there any association between COVID-19 severity and immunosuppressive therapy?
作者信息
Hormati Ahmad, Ghadir Mohammad Reza, Zamani Farhad, Khodadadi Javad, Khodadust Fatemeh, Afifian Mahboubeh, Aminnejad Reza, Ahmadpour Sajjad
机构信息
Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran; Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.
Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran.
出版信息
Immunol Lett. 2020 Aug;224:12-13. doi: 10.1016/j.imlet.2020.05.002. Epub 2020 May 28.
Abstract
摘要
相似文献
1
Are there any association between COVID-19 severity and immunosuppressive therapy?2019冠状病毒病的严重程度与免疫抑制治疗之间是否存在关联？
Immunol Lett. 2020 Aug;224:12-13. doi: 10.1016/j.imlet.2020.05.002. Epub 2020 May 28.
2
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.抗CD20免疫抑制疾病改善疗法与新型冠状病毒肺炎
Mult Scler Relat Disord. 2020 Jun;41:102135. doi: 10.1016/j.msard.2020.102135. Epub 2020 Apr 18.
3
The complement inhibitors in COVID-19: future expectations.新冠病毒肺炎中的补体抑制剂：未来展望
Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):6480-6481. doi: 10.26355/eurrev_202006_21628.
4
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.接受免疫抑制剂治疗的多发性硬化症患者：在整个新冠疫情范围内。
Rev Neurol (Paris). 2020 Jun;176(6):523-525. doi: 10.1016/j.neurol.2020.04.009. Epub 2020 Apr 27.
5
Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab.托珠单抗治疗后新型冠状病毒肺炎患者CT表现的有利变化
Diagn Interv Imaging. 2020 May;101(5):323-324. doi: 10.1016/j.diii.2020.03.010. Epub 2020 Mar 31.
6
Tocilizumab for COVID-19: a real 'miracle drug'?托珠单抗治疗新冠肺炎：一种真正的“神药”？
Infect Dis (Lond). 2020 Sep;52(9):681-682. doi: 10.1080/23744235.2020.1780307. Epub 2020 Jun 17.
7
COVID-19 in an elderly patient treated with secukinumab.一位接受司库奇尤单抗治疗的老年患者的新型冠状病毒肺炎
Dermatol Ther. 2020 Jul;33(4):e13580. doi: 10.1111/dth.13580. Epub 2020 May 27.
8
Tocilizumab in COVID-19: Beware the risk of intestinal perforation.托珠单抗治疗新型冠状病毒肺炎：谨防肠穿孔风险。
Int J Antimicrob Agents. 2020 Jul;56(1):106009. doi: 10.1016/j.ijantimicag.2020.106009. Epub 2020 May 7.
9
Treatment considerations for patients with pemphigus during the COVID-19 pandemic.COVID-19大流行期间天疱疮患者的治疗考量
J Am Acad Dermatol. 2020 Jun;82(6):e235-e236. doi: 10.1016/j.jaad.2020.04.005. Epub 2020 Apr 10.
10
Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review.托珠单抗用于新型冠状病毒肺炎的支持性治疗：一项系统评价
J Clin Virol. 2020 Jun;127:104380. doi: 10.1016/j.jcv.2020.104380. Epub 2020 Apr 21.
引用本文的文献
1
Diagnosis of Good Syndrome following Recurrent Coronavirus Disease-2019 Infections.2019年冠状病毒病反复感染后Good综合征的诊断
Case Rep Oncol. 2025 Jan 14;18(1):107-112. doi: 10.1159/000542928. eCollection 2025 Jan-Dec.
2
A genetically based computational drug repurposing framework for rapid identification of candidate compounds: application to COVID-19.一种基于基因的计算药物重新利用框架，用于快速识别候选化合物：应用于2019冠状病毒病
medRxiv. 2025 Jan 14:2025.01.10.25320348. doi: 10.1101/2025.01.10.25320348.
3
Gastrointestinal and Pancratohepatobiliary Cancers: A Comprehensive Review on Epidemiology and Risk Factors Worldwide.胃肠道和胰腺肝胆癌：全球流行病学与风险因素综述
Middle East J Dig Dis. 2022 Jan;14(1):5-23. doi: 10.34172/mejdd.2022.251. Epub 2022 Jan 30.
4
Inflammatory Bowel Disease Management during the COVID-19 Pandemic: A Literature Review.新冠疫情期间炎症性肠病的管理：文献综述
Middle East J Dig Dis. 2022 Apr;14(2):155-166. doi: 10.34172/mejdd.2022.269. Epub 2022 Apr 30.
5
Gastrointestinal and Liver Manifestations in COVID-19 Population.COVID-19患者的胃肠道和肝脏表现
Middle East J Dig Dis. 2021 Oct;13(4):281-286. doi: 10.34172/mejdd.2021.236. Epub 2021 Sep 3.
6
Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis.炎症性肠病与 COVID-19 结局：荟萃分析。
Sci Rep. 2022 Dec 9;12(1):21333. doi: 10.1038/s41598-022-25429-2.
7
Risk, Course, and Effect of SARS-CoV-2 Infection in Children and Adults with Chronic Inflammatory Bowel Diseases.患有慢性炎症性肠病的儿童和成人感染新型冠状病毒的风险、病程及影响
Children (Basel). 2021 Aug 30;8(9):753. doi: 10.3390/children8090753.
8
Gastrointestinal manifestations with COVID-19 virus infection: A Moroccan prospective study.新型冠状病毒感染的胃肠道表现：摩洛哥前瞻性研究。
Arab J Gastroenterol. 2021 Dec;22(4):305-309. doi: 10.1016/j.ajg.2021.07.004. Epub 2021 Jul 30.
9
IL10RB as a key regulator of COVID-19 host susceptibility and severity.白细胞介素10受体β作为新冠病毒宿主易感性和严重程度的关键调节因子。
medRxiv. 2021 Jun 2:2021.05.31.21254851. doi: 10.1101/2021.05.31.21254851.
10
Risk of Severe Covid-19 in Patients with Celiac Disease: A Population-Based Cohort Study.乳糜泻患者发生重症新型冠状病毒肺炎的风险：一项基于人群的队列研究
Clin Epidemiol. 2021 Feb 18;13:121-130. doi: 10.2147/CLEP.S294391. eCollection 2021.
本文引用的文献
1
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
2
The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat.2019 年冠状病毒病（COVID-19）爆发-新兴的全球健康威胁。
J Infect Public Health. 2020 Apr;13(4):644-646. doi: 10.1016/j.jiph.2020.02.033. Epub 2020 Mar 19.
3
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
4
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）和 2019 年冠状病毒病（COVID-19）：疫情和挑战。
Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17.
5
Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle.中国武汉不明原因肺炎疫情：谜团与奇迹
J Med Virol. 2020 Apr;92(4):401-402. doi: 10.1002/jmv.25678. Epub 2020 Feb 12.
Zotero 插件